bluuebunny/crossref_metadata_2025_split huggingface dataset:
Significance of Pathologic Response in Patients With Early and Locally Advanced Breast Cancer Treated With Neoadjuvant Chemotherapy in a Middle-Income Country. A Real-World Historical Cohort
Authors: Mantilla William , Gonzalez Maríafernanda , Rojas Sebastián , Borras-Osorio Mariana , Molano-Gonzalez Nicolas , Moran Diego , Guerra Joaquín Hernando , Romero Oscar , Munevar Isabel , Borda Molina Andres Armando , Preciado Beatriz Elena , Calidonio Camila Lema , Moran Ortiz Diego Efrain , Lopez Isabel Munevar , Guerra Villamizar Joaquin Hernando , Daza Buitrago Jorge Anibal , Osorio Mariana Borras , Lujan Piedrahita Mauricio Humberto , Medina Mauricio Lema , Mantilla Duran William Armando ,   on behalf of the ICAROS Research Group
Published: July 2024

PURPOSE Breast cancer (BC) is the most frequent neoplasm in women in Colombia and is associated with a higher mortality rate than in other countries and regions. Neoadjuvant chemotherapy (NACT) has become a standard treatment in locally advanced BC and provides an opportunity to improve clinical outcomes in BC. This study aims to describe characteristics, treatment patterns, and outcomes after NACT in a cohort of Colombian patients with BC. METHODS We performed a retrospective cohort study. We included adult patients with BC treated with NACT. Clinical charts were retrospectively reviewed. Descriptive statistics and time to event for overall survival analyses were performed. Recursive partitioning was performed for survival curves to assess the complex relationship between survival times and other variables. RESULTS Three hundred and fourteen patients were included for analysis. The pathologic complete response after neoadjuvant chemotherapy (ypCR) rate was 34.4%, with a higher ypCR in triple-negative BC (TNBC; 46.9%) and human epidermal growth factor receptor 2–positive BC (72.7%). Those who did not achieve ypCR had a higher percentage of death and relapse. The median follow-up was 4.9 years, with an 88.2% 5-year overall survival (OS). CONCLUSION A total of 62.6% of the total patients identified were not treated with NACT, indicating a low utilization. Our global ypCR rate was higher when compared with similar studies in Colombia, likely because of differences in the NACT treatment regimens. ypCR was only associated with OS in the TNBC subgroup, emphasizing the importance of pursuing ypCR in these patients. We consider the use of NACT a valuable opportunity to implement innovative treatment approaches that improve outcomes in Colombian patients with BC.
Unplanned Hospital Admissions in Patients With Solid Tumors in Brazil: Causes and Progressive Disease's Impact on Outcomes
Authors: Hidalgo Filho Cassio Murilo , Lazar Neto Felippe , Sobottka Vitor Pinheiro , da Rocha João Wilson , Stangler Lucas Tadeu Barrak , Andrade Heloisa Guedes , Benfatti Olivato Gustavo , Claro Mateus Zapparoli , Souza Danillo Zeferino de Oliveira , Yamamoto Victor Junji , Soares Mateus Marinho Nogueira , Estevez-Diz Maria del Pilar , Hoff Paulo M. , Bonadio Renata Colombo 
Published: July 2024

PURPOSE Most patients with cancer will be hospitalized throughout the disease course. However, most evidence on the causes and outcomes of these hospitalizations comes from administrative data or small retrospective studies from high-income countries. METHODS This study is a retrospective cohort of patients with solid tumors hospitalized from February 1, 2021, to December 31, 2021, in a tertiary cancer center in São Paulo, Brazil. We collected data on cancer diagnosis, symptoms at admission, hospitalization diagnosis, and survival clinical outcomes during in-hospital stay (in-hospital mortality) and after discharge (readmission rates and overall survival [OS]). Progressive disease (PD) diagnosis during admission was retrieved from manual chart review if explicitly stated by the attending physician. We modeled in-hospital mortality and postdischarge OS with logistic regression and Cox proportional hazards models, respectively. RESULTS A total of 3,726 unique unplanned admissions were identified. The most common symptoms at admission were pain (40.6%), nausea (16.8%), and dyspnea (16.1%). PD (34.0%), infection (31.1%), and cancer pain (13.4%) were the most frequent reasons for admission. The in-hospital mortality rate was 18.9%. Patients with PD had a high in-hospital mortality rate across all tumor groups and higher odds of in-hospital death (odds ratio, 3.5 [95% CI, 3.0 to 4.2]). The 7-, 30-, and 90-day readmission rates were 11.9%, 33.5%, and 54%, respectively. The postdischarge median OS (mOS) was 12.6 months (95% CI, 11.6 to 13.7). Poorer postdischarge survival was observed among patients with PD (mOS, 5 months v 18 months; P < .001; hazard ratio, 2.4 [95% CI, 2.1 to 2.6]). CONCLUSION PD is a common diagnosis during unplanned hospitalizations and is associated with higher in-hospital mortality rates and poorer OS after discharge. Oncologists should be aware of the prognostic implications of PD during admission and align goals of care with their patients.
Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): Primary analysis of a prospective, multicenter, response-adapted study.
Authors: Wang Fei , Wang Yongjiu , Xiong Bin , Yang Zhenlin , Wang Jingfen , Yao Yumin , Yu Lixiang , Fu Qinye , Li Liang , Zhang Qiang , Zheng Chao , Huang Shuya , Liu Liyuan , Liu Chun , Sun Huaibo , Mao Beibei , Yu Zhigang 
Published: July 2024

603 Background: The contribution of biological characteristics and treatment patterns to the survival difference between male and female breast cancer patients is understudied, which is controversial but fundamental in determining strategies for cancer treatment and survivorship care. To evaluate the efficacy and safety of additional pyrotinib in patients with HER2-positive breast cancer who had no early response to neoadjuvant trastuzumab in combination with chemotherapy. Methods: A prospective, multicenter, response-adapted study including patients diagnosed with HER2-positive breast cancer from 2020 to 2022 were conducted. A total of 129 female patients from 5 hospitals participated in this neoadjuvant setting study. The primary endpoint was pathological complete response ( pCR), defined as the absence of invasive cancer in both the breast and axilla as determined by a local pathologist after surgery (ypT0ypN0). Results: Among 129 enrolled participants, 62 (48.1%) were identified as MRI-responders (Cohort A), 26 non-responders received 4 more cycles of TCbH (Cohort B), while 41 received additional pyrotinib (Cohort C). The pCR rates were 30.6% (95%CI: 20.6%-43.0%) in Cohort A, 15.4% (95%CI: 6.2%-33.5%) in Cohort B and 29.3% (95%CI: 17.6%-44.5%) in Cohort C. Similar difference patterns of breast pCR rates across 3 cohorts were observed. Multivariable logistic regression analyses showed that, in comparison to those in Cohort A, patients in Cohort C had comparable probability of pCR (OR=1.03, 95%CI: 0.40 to 2.67). The most common adverse events among patients who received pyrotinib were diarrhoea, anaemia, and erythropenia, and no cardiovascular event was observed. Participants with low TMB and no RTK-RAS mutation had a quite low pCR rate of 4%. Conclusions: The addition of pyrotinib to trastuzumab increases the pCR rates among patients who had no early response to neoadjuvant trastuzumab. Further studies are warranted to identify biomarkers predicting those who may benefit from pyrotinib in addition to trastuzumab. Clinical trial information: NCT03847818 .
Phase 1 study of multiple intracerebral doses of a neural stem cell-based oncolytic virotherapy for treatment of recurrent high-grade gliomas.
Authors: Portnow Jana , Badie Behnam , Blanchard Suzette , D'Apuzzo Massimo , Nath Aritro , Synold Timothy W. , Barthel Floris , Mooney Rachael , Ngai Gary , Minev Boris , Santidrian Antonio F. , Aboody Karen S. 
Published: July 2024

TPS2102 Background: Oncolytic virotherapy is a promising cancer treatment that can directly lyse tumor cells as well as induce anti-tumor immune responses. However, clinical efficacy has been limited by rapid immune-mediated clearance of oncolytic viruses (OVs). Neural stem cell (NSC) carriers are tumor tropic and can protect OVs, allowing time for viral amplification and better distribution throughout tumors. HB1.F3.CD.21 is an immortalized, clonal human NSC line with demonstrated stability, scalability, and safety in humans (NCT01172964, NCT02015819). This NSC line was genetically modified to produce a tumor-selective, conditionally replicating adenovirus (CRAd; NSC-CRAd-S-pk7). A first-in-human clinical trial (NCT03072134) in newly diagnosed high grade glioma patients showed safety of a single intracerebral dose of NSC-CRAd-S-pk7 and determined the maximum feasible dose (MFD). Here we describe the next early phase clinical trial for development of this new NSC-based oncolytic virotherapy. Methods: This phase 1 study is evaluating the safety and feasibility of intracerebrally administering up to 4 weekly doses of NSC-CRAd-S-pk7 in patients with recurrent high grade gliomas. Study participants initially undergo resection of tumor followed by manual injection of the first dose of study agent into the wall of the resection cavity. Two Rickham catheters are also placed: one in the surgical cavity for subsequent administration of weekly doses of NSC-CRAd-S-pk7 and the other in the lateral ventricle to obtain serial CSF samples for correlative immunologic and safety studies. Two weeks after receiving the last dose of NSC-CRAd-S-pk7, participants undergo a second surgical procedure to remove the Rickham catheters and obtain post-treatment tissue samples. All participants are treated with the same dose of NSC-CRAd-S-pk7: 150 x 106 NSCs/1.875 x 1011 viral particles, which is the MFD that was determined in the first-in-human study. A multi-cycle toxicity equivalence range design is used to define the escalation and de-escalation rules for evaluating the four treatment schedules. Once the maximum tolerated number of weekly cycles is determined, an expansion cohort will be assessed. The study’s secondary objectives include assessing the biologic activity, biodistribution, immunogenicity, safety, and preliminary clinical efficacy of NSC-CRAd-S-pk7. The estimated study sample size is 24-30 participants. Progress: The first patient began study treatment in May 2023. We are currently enrolling participants to Treatment Schedule 4. Multi-center sites for enrolling patients to the expansion cohort include City of Hope, Stanford University, Wake Forest University, and Northwestern University. Clinical trial information: NCT05139056 .
influence of the Dark Triad on various aspects of life – a review
Authors: Kozicz Michał Andrzej , Cuper Paulina , Jastrzębska Ilona , Bilecki Krzysztof , Gugulski Hubert , Bado Michał , Nowoświat Patrycja , Cuper Michalina 
Published: July 2024

Introduction: The Dark Triad is a construct devised by Paulhus and Williams in 2002. It comprises of three personality disorders: Narcissism, Machiavellianism and psychopathy, that are believed to be debilitating both to people exhibiting these traits and their social environment.
Aim of the Study: The aim of the study was to collect and analyse current literature regarding the Dark Triad and the influence of its components on different areas of functioning.
Methods and Materials: Extensive research was conducted using PubMed and Google Scholar, with the primary focus on literature from the past 5 years. These databases were searched using “the Dark Triad” and its components names as entries to gather articles. Additionally, references from selected articles were included in the analysis.
Results: Our article showed that the components of the Dark Triad influence many areas of functioning, although this influence is not always negative.
Having all the traits of the Dark Triad is more likely to induce immoral behaviour than having the individual traits in isolation. Thus, further research of the Dark Triad is needed, especially regarding different facets of its components. Devising more in-depth questionnaires that would cover all sub-divisions of the Dark Triad components would largely bolster the research in this field.
Business Model Choice for Heavy Equipment Manufacturers
Authors: Blaettchen Philippe , Taneri Niyazi , Hasija Sameer 
Published: July 2024

Finding the Right Business Model for Durable Goods Technological advances enable new ways for customers to access durable goods such as heavy equipment without the need for ownership. In “Business Model Choice for Heavy Equipment Manufacturers,” P. Blaettchen, N. Taneri, and S. Hasija analyze the resulting business models available to manufacturers, considering that manufacturers need to effectively coordinate their sales strategy with their highly profitable after-sales service activities and take into account secondary markets. Employing a game-theoretic framework, the authors show how different equipment characteristics lead to different optimal business model designs. They provide a comprehensive overview of when manufacturers should rely on emerging models based on servicization or peer-to-peer sharing and when it pays to retain a traditional model based on sales. Drawing on a novel framework for analyzing a business model’s environmental impact, they further show that emerging models can create win-win situations for the manufacturer and the environment.
Microlens arrays for multichannel laser-to-waveguide coupling
Authors: Kunze K. , Gossler C. , Peters V. , Keppeler D. , Moser T. , Schwarz U. T. 
Published: July 2024

An optical multichannel coupling system for coupling laser arrays to waveguide arrays is developed. Based on a microlens array, the system enables coupling of nine individual optical channels, with one aspheric microlens per channel at a lateral channel pitch of 100 µm. The design process criteria for the proposed microlenses, with 97 µm diameter and working distances from laser to lens and lens to waveguide of 150 µm and 275 µm, respectively, are described. The microlens array is fabricated on a 4mm×2mm×0.41mm fused silica chip and contains an orthogonal grid with 32×16 microlenses, of which a row of nine adjacent microlenses is used for coupling. Uniform coupling over all channels can be achieved, as well as specific coupling for each channel individually with less than −13.5dB crosstalk. The coupling system is designed for optical neural stimulators.
Fabrication of liquid-filled zoom compound eyes with a tunable focal length
Authors: Chen Qilong , Bian Zhenyao , Wang Haoran , Chang Xueying , Fang Yong , Lu Hongbo , Xu Miao 
Published: July 2024

The conventional bionic compound eye system encounters challenges
associated with a complex zoom structure, susceptibility to wear, and
elevated costs. In this paper, a preparation method of liquid-filled
zoom compound eyes is proposed. A polydimethylsiloxane (PDMS) film is
integrated with a microfluidic chamber composed of polymethyl
methacrylate (PMMA). The microlens array (MLA, hexagonal array,
diameter 800 µm, center distance 850 µm) on the PDMS
film is prepared by a wettability-guided dipping method. The sub-eye
focal length on zoom compound eyes (ZCEs) is 1.42 mm. By
controlling the volume of deionized (DI) water injected into the
chamber from 2.41 to 2.71cm3, the focal length of the main lens is
adjusted from infinity to 55.51 mm, and the FOV is adjusted
from 32° to 58°. This large aperture ZCE combines the advantages of
monocular and compound eyes. This method has great potential for
advanced micro-optical devices with a wide field of view and tunable
imaging capabilities.
The impact of positive surgical margin parameters and pathological stage on biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis
Authors: Guo Hong , Zhang Lei , Shao Yuan , An Kunyang , Hu Caoyang , Liang Xuezhi , Wang Dongwen 
Published: July 2024

Background
To systematically review and perform a meta-analysis on the predictive value of the primary Gleason grade (PGG) at the positive surgical margin (PSM), length of PSM, number of PSMs, and pathological stage of the primary tumor on biochemical recurrence (BCR) in patients with prostate cancer (PCa) after radical prostatectomy (RP).

Methods
A systematic literature search was performed using electronic databases, including PubMed, EMBASE, Cochrane Library, and Web of Science, from January 1, 2005, to October 1, 2023. The protocol was pre-registered in PROSPERO. Subgroup analyses were performed according to the different treatments and study outcomes. Pooled hazard ratios with 95% confidence intervals were extracted from multivariate analyses, and a fixed or random effect model was used to pool the estimates. Subgroup analyses were performed to explore the reasons for the heterogeneity.

Results
Thirty-one studies that included 50,028 patients with PCa were eligible for this meta-analysis. The results showed that, compared to PGG3, PGG4/5 was associated with a significantly increased risk of BCR. Compared with PSM ≤3 mm, PSM ≥3 mm was associated with a significantly increased risk of BCR. Compared with unifocal PSM, multifocal PSM (mF-PSM) was associated with a significantly increased risk of BCR. In addition, pT >2 was associated with a significantly increased risk of BCR compared to pT2. Notably, the findings were found to be reliable based on the sensitivity and subgroup analyses.

Conclusions
PGG at the PSM, length of PSM, number of PSMs, and pathological stage of the primary tumor in patients with PCa were found to be associated with a significantly increased risk of BCR. Thus, patients with these factors should be treated differently in terms of receiving adjunct treatment and more frequent monitoring. Large-scale, well-designed prospective studies with longer follow-up periods are needed to validate the efficacy of these risk factors and their effects on patient responses to adjuvant and salvage therapies and other oncological outcomes.
Migraine and gastroesophageal reflux disease: Disentangling the complex connection with depression as a mediator
Authors: Shen Zixiong , Bian Yewen , Huang Yao , Zhou Wenhua , Chen Hao , Zhou Xia , Li Liuying 
Published: July 2024

Objective
Gastroesophageal reflux disease (GERD) and migraine are public health concerns worldwide. No observational study has conclusively elucidated the causal relationship between these two conditions. We employed Mendelian randomization (MR) methods to explore the potential causal links between GERD and migraine.

Methods
Genome-wide association studies were subjected to MR to infer the causality between GERD and migraine. Bidirectional two-sample MR was performed to establish causal relationships. Multivariable MR analysis was conducted to adjust potential confounding factors, and mediation MR analysis was utilized to assess the role of depression between GERD and migraine as a mediator. We primarily utilized the inverse variance weighted method (IVW) and sensitivity analysis methods, including MR-Egger, weighted median, and leave-one-out methods. We assessed heterogeneity and pleiotropy to ensure the reliability of the results.

Results
Bidirectional two-sample MR revealed a positive causal effect of GERD on migraine (IVW: OR = 1.49, 95% CI: 1.34–1.66, p = 3.70E-13). Migraine did not increase the risk of GERD (IVW: OR = 1.07, 95% CI: 0.98–1.17, p = 0.1139). Multivariable MR indicated that the positive causal effect of GERD on migraine remained after adjustment for factors, such as smoking, alcohol consumption, obesity, type 2 diabetes, and depression. Mediation MR revealed that depression mediated 28.72% of GERD’s effect on migraine. MR analysis was supported by all sensitivity analyses and was replicated and validated in another independent dataset on migraine.

Conclusion
Our findings elucidate the positive causal effect of GERD on migraine and underscores the mediating role of depression in increasing the risk of migraine due to GERD. Effective control of GERD, particularly interventions targeting depression, may aid in preventing the occurrence of migraine. Future research should delve deeper into the specific pathophysiological mechanisms through which GERD affects migraine risk, facilitating the development of more effective drug targets or disease management strategies.
Knowledge, attitude and practice (KAP) on food-drug interaction (FDI) among pharmacists working in government health facilities in Sabah, Malaysia
Authors: Khong Jackie Ho Chit , Tuan Mahmood Tuan Mazlelaa , Tan Sze Ling , Voo James Yau Hon , Wong See Wan 
Published: July 2024

BackgroundFood-drug interaction (FDI) is prevalent in our day-to-day life. Widely recognised as drug expert, pharmacists are responsible to provide patient education, including on FDI, to ensure optimum safety and efficacy of treatment. Most pharmacists have knowledge and experience regarding FDI to certain extent. However, the level of knowledge, attitude and practice (KAP) towards FDI among pharmacists were yet to elucidated for many countries, including for Malaysia.ObjectiveThis study aims to assess pharmacists’ KAP on FDI, their inter-association, as well as association with sociodemographic characteristics in Sabah, Malaysia.Methods & materialsA cross-sectional study was conducted from 1 to 31 May 2023, using online, self-administered Google Form questionnaire, involving 24 government hospitals and 113 government health clinics in Sabah.ResultsA total of 273 (or 35.5%) out of 768 pharmacists responded. Over two-third were female and serving government hospitals (79.6%). Mean score of KAP were 72.5 ± 14.3%, 93.2 ± 8.3% and 56.0 ± 16.7%, respectively, reflected good attitude but moderate knowledge and practice. Knowledge gaps identified include common medications such as paracetamol and metformin.Additionally, 28.2% respondents reported lack of FDI coverage during undergraduate, while merely 17.2% have received formal training on FDI after started working. Although 89.0% respondents agree that informing patients about possible FDIs is their responsibility, only 35.9% of the respondents usually or always practiced this. Such discrepancy maybe attributed to insufficient pharmacists’ knowledge on FDI, where pharmacists with good level of knowledge have almost 2 times higher odd for good level of practice, compared to those with poor/moderate knowledge (odds ratio, OR: 1.92; 95% CI 1.02–3.61; p = 0.040) in this study.ConclusionThere are significant training gaps to be filled in. Pharmacist possessing good knowledge is a prerequisite for better pharmacy practice. Adequate education strategies covering FDI should be emphasised for all pharmacy undergraduates and practising pharmacists.